Company intelligence / Profile preview

Synucure Therapeutics

Montreal, Québec, Canada

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Synucure Therapeutics is developing a novel formulation of the small molecule cysteamine, which has demonstrated disease-modifying potential in preclinical animal and cell models of Parkinson’s disease, but there are currently no active clinical trials or published clinical results.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Investissement Québec (government agency investment partnership)Private investors (not named)CQDM (support/advisory role during investment diligence)

Beyond the preview

Go deeper on Synucure Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synucure Therapeutics.

Explore the full profile